Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rapgef2tm1.1Hous mutation
(1 available);
any
Rapgef2 mutation
(82 available)
|
|
|
mortality/aging
|
|
• 15% of tamoxifen-treated mice die at E18.5 to E20.5
|
hematopoietic system
|
N |
• mice exhibit normal adult hematopoiesis
|
immune system
|
N |
• mice exhibit normal B cell and T cell development
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rapgef2tm1.1Hous mutation
(1 available);
any
Rapgef2 mutation
(82 available)
Tg(VAV1-cre)1Graf mutation
(1 available)
|
|
|
hematopoietic system
|
N |
• mice exhibit normal adult hematopoiesis
|
immune system
|
N |
• mice exhibit normal B cell and T cell development
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rapgef2tm1.1Hous mutation
(1 available);
any
Rapgef2 mutation
(82 available)
Tg(Cd4-cre)1Cwi mutation
(10 available)
|
|
|
hematopoietic system
|
N |
• mice exhibit normal adult hematopoiesis
|
immune system
|
N |
• mice exhibit normal B cell and T cell development
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rapgef2tm1.1Hous mutation
(1 available);
any
Rapgef2 mutation
(82 available)
Tg(Mx1-cre)1Cgn mutation
(7 available)
|
|
|
hematopoietic system
|
N |
• pIpC-treated mice exhibit normal adult hematopoiesis
|
immune system
|
N |
• pIpC-treated mice exhibit normal B cell and T cell development
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rapgef2tm1.1Hous mutation
(1 available);
any
Rapgef2 mutation
(82 available)
Tg(CAG-cre/Esr1*)5Amc mutation
(9 available)
|
|
|
mortality/aging
|
|
• most mice treated with tamoxifen at E11.5 and E13.5 die E17.5 and E18.5 with remaining mice dying at E19.5 to E10.5
• however, mice treated with tamoxifen at E17.5 and E19.5 exhibit the same lethality as in similarly treated Rapgef2tm1.1Hous homozygotes
|
hematopoietic system
|
|
• mice treated with tamoxifen at E11.5 and E13.5 exhibit impaired fetal liver hematopoiesis with reduced differentiation of erythroid progenitor cells compared with similarly treated Rapgef2tm1.1Hous homozygotes
|
|
|
• at E16.5 in the livers of mice treated with tamoxifen at E11.5 and E13.5
|
cardiovascular system
|
|
• at E17.5, mice treated with tamoxifen at E11.5 and E13.5 lack major embryonic blood vessels unlike wild-type mice
|
growth/size/body
|
|
• in mice treated with tamoxifen at E17.5 and E19.5
|
liver/biliary system
|
|
• at E16.5 in mice treated with tamoxifen at E11.5 and E13.5
|
integument
|
|
• at E17.5 in mice treated with tamoxifen at E11.5 and E13.5
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rapgef2tm1.1Hous mutation
(1 available);
any
Rapgef2 mutation
(82 available)
Tg(Cdh5-cre)7Mlia mutation
(1 available)
|
|
|
hematopoietic system
|
N |
• mice exhibit normal adult hematopoiesis
|
immune system
|
N |
• mice exhibit normal B cell and T cell development
|
Analysis Tools
